Kidvid Eye Drop contains Atropine 0.01% w/v, a parasympatholytic agent primarily used in ophthalmology to induce mydriasis and cycloplegia. Atropine acts by competitively blocking muscarinic receptors in the iris sphincter and ciliary muscles, resulting in pupil dilation and paralysis of accommodation. This low concentration formulation is typically employed in pediatric patients to manage conditions such as amblyopia, accommodative esotropia, and to facilitate comprehensive ocular examinations by preventing accommodation. Kidvid Eye Drop is administered topically, with dosage and frequency determined by the treating ophthalmologist based on the clinical indication and patient response. The onset of action generally occurs within 30 to 40 minutes, with effects lasting up to 7 to 14 days due to the prolonged receptor blockade. Caution is advised in patients with a history of hypersensitivity to atropine or other anticholinergic agents, and it should be used cautiously in individuals with narrow-angle glaucoma due to the risk of precipitating angle closure. Common adverse effects include transient photophobia, blurred vision, and local irritation. Proper administration technique and adherence to prescribed dosing are essential to minimize systemic absorption and potential side effects. Kidvid Eye Drop should be stored at controlled room temperature, protected from light, and kept out of reach of children.